Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/26/2005WO2005046687A1 Use of selective opiate receptor modulators in the treatment of neuropathy
05/26/2005WO2005046686A1 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
05/26/2005WO2005046685A1 Substituted piperidines for the treatment of metabolic syndrome
05/26/2005WO2005046684A1 Once daily dosage forms of trospium
05/26/2005WO2005046683A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
05/26/2005WO2005046682A1 Therapeutic compounds and uses thereof
05/26/2005WO2005046681A1 Cci-779 for treating mantle cell lymphoma
05/26/2005WO2005046680A1 Percutaneous absorption type cerebral protective agent
05/26/2005WO2005046678A1 Cancer treatment method
05/26/2005WO2005046677A2 At1-receptor antagonists for treating nephrotic syndrome
05/26/2005WO2005046676A1 Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
05/26/2005WO2005046675A2 Methods for enhancing glutathione peroxidase activity
05/26/2005WO2005046674A2 Antibacterial compositions
05/26/2005WO2005046673A1 A method of treating premenstrual dysphoric disorder with escitalopram
05/26/2005WO2005046672A2 Use of glucosidase inhibitors for therapy of mucovisidosis
05/26/2005WO2005046671A1 Method for preparing submicron particles of paclitaxel
05/26/2005WO2005046670A1 Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
05/26/2005WO2005046669A1 Treatment and prevention of liver disease associated with parenteral nutrition (pn)
05/26/2005WO2005046668A1 Preventive/therapeutic agent for speech disorder
05/26/2005WO2005046667A2 System a transport inhibitors for treating or preventing neuropsychiatric disorders
05/26/2005WO2005046666A1 Pharmaceutical composition for treating stress incontinence and/or mixed incontinence
05/26/2005WO2005046665A1 Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
05/26/2005WO2005046664A1 Pharmaceutical composition consisting of a beta-3 adrenoceptor agonist and an alpha agonist
05/26/2005WO2005046663A1 Compositions of quaternary ammonium containing bioavailability enhancers
05/26/2005WO2005046662A2 Hdl-boosting combination therapy complexes
05/26/2005WO2005046661A2 Use of nitric oxide donors for the treatment of drug addiction
05/26/2005WO2005046660A1 MODULATING SUBSTANCES OF THE NITRIC OXID (NO) - CYCLIC GUANOSINE - 3’,5’- MONOPHOSPHATE (cGMP) SIGNALING PATHWAY FOR THE TREATMENT OF DENTAL DISORDERS
05/26/2005WO2005046659A2 Migraine treatments including isovaleramide compounds and serotonin agonists
05/26/2005WO2005046658A2 Methods of modulating angiogenesis and cancer cell proliferation
05/26/2005WO2005046657A2 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
05/26/2005WO2005046656A2 Use of 5 - chloro-1- (2, 6 - dichloro - 4 - trifluoromethylphenyl) - 4 - (4, 5 - dicyano - 1h - imidazol - 2yl) -3 - methyl - 1h - pyrazole in systemic control of acarid infestation on animals
05/26/2005WO2005046653A1 Antiphlogistic and analgesic plaster comprising felbinac compound
05/26/2005WO2005046652A1 Controlled release ketoprofen formulation
05/26/2005WO2005046651A1 Liquid filled capsules of doxycycline
05/26/2005WO2005046650A1 Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor
05/26/2005WO2005046648A1 Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine
05/26/2005WO2005046644A1 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
05/26/2005WO2005046643A2 Method for drug loading in liposomes
05/26/2005WO2005046641A2 Compositions and methods for treating a posterior segment of an eye
05/26/2005WO2005046637A2 Pharmaceutical formulations employing short-chain sphingolipids and their use
05/26/2005WO2005046634A2 Gastric juice-resistant form of administration
05/26/2005WO2005046630A1 Hair restorer compositions and antipruritic agent
05/26/2005WO2005046623A1 Combined cosmetic or therapeutic preparation
05/26/2005WO2005046618A2 Methods of treating eczema
05/26/2005WO2005046615A2 Compositions for treatment of central nervous system mediated disorders
05/26/2005WO2005046612A2 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005WO2005046611A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005WO2005046610A2 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
05/26/2005WO2005046608A2 Novel compound, corresponding compositions, preparation and/or treatment methods
05/26/2005WO2005046607A2 Combinations for the treatment of proliferative diseases
05/26/2005WO2005046604A2 Heteroaryl-hydrazone compounds
05/26/2005WO2005046603A2 Pyridine compounds
05/26/2005WO2005046601A2 4-phenyl piperdine sulfonyl glycine transporter inhibitors
05/26/2005WO2005046599A2 Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
05/26/2005WO2005046595A2 Hif-1 inhibitors and methods of use thereof
05/26/2005WO2005046594A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005WO2005046592A2 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
05/26/2005WO2005046590A2 Methods for synthesizing quinolinone compounds
05/26/2005WO2005046589A2 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005WO2005046588A2 Compounds, compositions, and methods
05/26/2005WO2005046586A2 M3 muscarinic acetylcholine receptor antagonists
05/26/2005WO2005046584A2 Stimulation of hair growth by ginkgo biloba flavanoids
05/26/2005WO2005046580A2 Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
05/26/2005WO2005046578A2 Isoquinolinone potassium channel inhibitors
05/26/2005WO2005046574A2 Compositions containing melon extracts
05/26/2005WO2005046567A2 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
05/26/2005WO2005046566A2 Stable gabapentin containing composition
05/26/2005WO2005046565A2 Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
05/26/2005WO2005046564A2 Diagnosis and treatment of liver fibrosis
05/26/2005WO2005046562A2 Use of sulfated hyaluronic acid
05/26/2005WO2005046438A2 Internal clamp for surgical procedures
05/26/2005WO2005046434A2 Compositions and methods for diagnosing and treating mental disorders
05/26/2005WO2005046360A2 Carbohydate and electrolyte replacement composition
05/26/2005WO2005046358A1 Method of using whole olive and food having activity against helicobacter pylori
05/26/2005WO2005046318A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
05/26/2005WO2005037848A3 Glycerophospholipids containing omega-3 and omega-6 fatty acids
05/26/2005WO2005030791A3 Isoquinolinone potassium channel inhibitors
05/26/2005WO2005030678A3 AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
05/26/2005WO2005030225A3 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
05/26/2005WO2005030129A3 Quinoline potassium channel inhibitors
05/26/2005WO2005030127A3 Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
05/26/2005WO2005028438A9 Novel piperidine derivative
05/26/2005WO2005027951B1 Method for controlling angiogenesis in animals
05/26/2005WO2005025549A3 Multi-layer transdermal drug delivery device
05/26/2005WO2005020959A3 Novel drug compositions and dosage forms of topiramate
05/26/2005WO2005020901A3 Delivery of a therapeutic agent in a formulation for reduced toxicity
05/26/2005WO2005014001A9 Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain
05/26/2005WO2005013957A3 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof
05/26/2005WO2005009411B1 Particles containing an active agent in the form of a co-precipitate
05/26/2005WO2005009361A3 Method of treating hit patients with argatroban
05/26/2005WO2005007082A3 Treatment of chronic bacterial infection
05/26/2005WO2005002582A3 Trp-p8 active compounds and therapeutic treatment methods
05/26/2005WO2005000331A3 Compositions for the treatment and prevention of degenerative joint disorders
05/26/2005WO2005000318B1 Method of inducing apoptosis and inhibiting cardiolipin synthesis
05/26/2005WO2005000245A3 Compositions and methods for increasing telomerase activity
05/26/2005WO2004112719A8 Chemical compounds
05/26/2005WO2004112695B1 Methods and compositions for delivery of catecholic butanes for treatment of obesity
05/26/2005WO2004110416A3 Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration
05/26/2005WO2004108664A3 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same
05/26/2005WO2004108162B1 Controlled release pharmaceutical composition
1 ... 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 ... 7860